An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration / 浙江大学学报(英文版)(B辑:生物医学和生物技术)
Journal of Zhejiang University. Science. B
; (12): 327-332, 2018.
Article
in En
| WPRIM
| ID: wpr-1010392
Responsible library:
WPRO
ABSTRACT
OBJECTIVE@#To evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD).@*METHODS@#In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization.@*RESULTS@#Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy (P<0.05). The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients (Z=-2.844, P=0.009). Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy (P<0.05), and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later (P>0.05).@*CONCLUSIONS@#IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Vision, Ocular
/
Treatment Outcome
/
Choroidal Neovascularization
/
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor A
/
Wet Macular Degeneration
/
Intravitreal Injections
/
Ranibizumab
/
Inflammation
/
Macular Degeneration
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Journal of Zhejiang University. Science. B
Year:
2018
Type:
Article